Citadel Advisors
AVXL icon

Citadel Advisors’s Anavex Life Sciences AVXL Stock Holding History

Citadel Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$182K Sell
59,200
-162,900
-73% -$706K ﹤0.01% 11508
2025
Q4 		$791K Buy
222,100
+141,600
+176% +$867K ﹤0.01% 7946
2025
Q3 		$716K Buy
80,500
+48,000
+148% +$487K ﹤0.01% 8287
2025
Q2 		$300K Sell
32,500
-5,100
-14% -$43.5K ﹤0.01% 9831
2025
Q1 		$323K Sell
37,600
-17,600
-32% -$166K ﹤0.01% 9418
2024
Q4 		$593K Sell
55,200
-4,600
-8% -$35.4K ﹤0.01% 8185
2024
Q3 		$340K Buy
59,800
+21,600
+57% +$125K ﹤0.01% 9061
2024
Q2 		$161K Sell
38,200
-7,600
-17% -$30.7K ﹤0.01% 10231
2024
Q1 		$233K Sell
45,800
-95,600
-68% -$538K ﹤0.01% 10003
2023
Q4 		$1.32M Buy
141,400
+14,600
+12% +$101K ﹤0.01% 6127
2023
Q3 		$831K Buy
126,800
+6,600
+5% +$52.5K ﹤0.01% 6968
2023
Q2 		$977K Buy
120,200
+71,000
+144% +$608K ﹤0.01% 6496
2023
Q1 		$422K Sell
49,200
-129,900
-73% -$1.3M ﹤0.01% 8654
2022
Q4 		$1.66M Buy
179,100
+60,600
+51% +$647K ﹤0.01% 5839
2022
Q3 		$1.22M Sell
118,500
-13,400
-10% -$141K ﹤0.01% 6550
2022
Q2 		$1.32M Buy
131,900
+7,800
+6% +$73.9K ﹤0.01% 6398
2022
Q1 		$1.53M Buy
124,100
+36,000
+41% +$443K ﹤0.01% 6688
2021
Q4 		$1.53M Sell
88,100
-38,700
-31% -$735K ﹤0.01% 6846
2021
Q3 		$2.28M Sell
126,800
-66,300
-34% -$1.32M ﹤0.01% 6027
2021
Q2 		$4.41M Buy
193,100
+111,000
+135% +$1.64M ﹤0.01% 4706
2021
Q1 		$1.23M Buy
82,100
+23,500
+40% +$257K ﹤0.01% 7587
2020
Q4 		$316K Buy
58,600
+38,800
+196% +$204K ﹤0.01% 8980
2020
Q3 		$90K Buy
+19,800
New +$85.2K ﹤0.01% 9333
2020
Q2 		– Sell
-34,200
Closed -$108K – 9748
2020
Q1 		$108K Sell
34,200
-59,600
-64% -$208K ﹤0.01% 8582
2019
Q4 		$243K Buy
93,800
+24,200
+35% +$63.5K ﹤0.01% 7894
2019
Q3 		$220K Buy
69,600
+35,800
+106% +$103K ﹤0.01% 8027
2019
Q2 		$114K Buy
33,800
+15,400
+84% +$47.8K ﹤0.01% 8487
2019
Q1 		$56K Sell
18,400
-33,600
-65% -$80.3K ﹤0.01% 8777
2018
Q4 		$81K Sell
52,000
-16,700
-24% -$37.9K ﹤0.01% 8334
2018
Q3 		$188K Buy
68,700
+20,200
+42% +$57K ﹤0.01% 8252
2018
Q2 		$127K Buy
48,500
+19,300
+66% +$53.9K ﹤0.01% 8134
2018
Q1 		$81K Buy
29,200
+13,000
+80% +$36.7K ﹤0.01% 7784
2017
Q4 		$52K Buy
+16,200
New +$63.8K ﹤0.01% 7616
2017
Q3 		– Sell
-10,800
Closed -$57K – 7510
2017
Q2 		$57K Sell
10,800
-2,100
-16% -$12.1K ﹤0.01% 7064
2017
Q1 		$74K Sell
12,900
-6,000
-32% -$31K ﹤0.01% 6951
2016
Q4 		$75K Buy
+18,900
New +$67.3K ﹤0.01% 6769
2016
Q3 		– Sell
-24,500
Closed -$150K – 7219
2016
Q2 		$150K Buy
24,500
+10,200
+71% +$49.3K ﹤0.01% 6024
2016
Q1 		$70K Buy
14,300
+8,700
+155% +$38.3K ﹤0.01% 6162
2015
Q4 		$31K Buy
+5,600
New +$39.8K ﹤0.01% 7639

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Citadel Advisors's AVXL Position: Q1 2026 in Review

Citadel Advisors increased its Anavex Life Sciences (AVXL) stake by 392% in Q1 2026, buying an estimated $1.93M and bringing the position to 559,435 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #6419.

Citadel Advisors first reported a position in AVXL in Q4 2015 and has held it in 36 quarters since. The position peaked at $7M in Q2 2022. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • Citadel Advisors held 559,435 shares of Anavex Life Sciences worth $1.72M as of Q1 2026.
  • Citadel Advisors bought 445,696 Anavex Life Sciences shares in Q1 2026, an estimated $1.93M.
  • Anavex Life Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6419 holding.
  • Citadel Advisors first reported a position in Anavex Life Sciences in Q4 2015 and has held it in 36 quarters since.
  • Citadel Advisors's Anavex Life Sciences position peaked at $7M in Q2 2022.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.